See more : Citycon Oyj (COYJF) Income Statement Analysis – Financial Results
Complete financial analysis of Inventiva S.A. (IVA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inventiva S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Pelayaran Nasional Ekalya Purnamasari Tbk (ELPI.JK) Income Statement Analysis – Financial Results
- Career Point Limited (CAREERP.NS) Income Statement Analysis – Financial Results
- Public Joint Stock Company Inter RAO UES (IRAO.ME) Income Statement Analysis – Financial Results
- Companhia Energética de Brasília – CEB (CEBR6.SA) Income Statement Analysis – Financial Results
- Lakeland Industries, Inc. (LAKE) Income Statement Analysis – Financial Results
Inventiva S.A. (IVA)
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.48M | 12.18M | 4.19M | 372.00K | 7.00M | 3.20M | 6.52M | 9.45M | 4.87M | 3.28M | 3.06M |
| Cost of Revenue | -23.00K | 995.00K | 1.02M | 846.00K | 0.00 | 967.00K | 1.24M | 1.49M | 1.40M | 1.52M | 1.68M |
| Gross Profit | 17.50M | 11.18M | 3.18M | -474.00K | 7.00M | 2.23M | 5.28M | 7.96M | 3.47M | 1.76M | 1.38M |
| Gross Profit Ratio | 100.13% | 91.83% | 75.75% | -127.42% | 100.00% | 69.75% | 81.05% | 84.27% | 71.18% | 53.59% | 45.11% |
| Research & Development | 110.01M | 60.47M | 48.45M | 23.72M | 33.79M | 31.64M | 26.73M | 22.14M | 19.64M | 16.28M | 13.75M |
| General & Administrative | 13.85M | 12.91M | 11.16M | 8.50M | 4.51M | 4.51M | 4.09M | 3.25M | 3.11M | 2.65M | 2.71M |
| Selling & Marketing | 1.76M | 2.58M | 364.00K | 563.00K | 8.00K | 9.00K | 37.78K | 50.56K | 112.70K | 247.32K | 325.57K |
| SG&A | 15.61M | 15.50M | 11.52M | 9.06M | 4.51M | 4.52M | 4.12M | 3.30M | 3.22M | 2.90M | 3.04M |
| Other Expenses | -5.43M | -6.68M | -3.66M | -2.69M | -2.09M | 257.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Cost & Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Interest Income | 945.00K | 390.00K | 5.48M | 226.00K | 157.00K | 120.00K | 276.62K | 230.18K | 227.63K | 273.84K | 42.65K |
| Interest Expense | 5.18M | 707.00K | 2.64M | 66.00K | 3.00K | 4.00K | 5.32K | 7.55K | 6.06K | 2.94K | 630.00 |
| Depreciation & Amortization | 2.60M | 1.68M | 927.00K | 1.01M | 1.46M | 949.00K | 1.24M | 1.49M | 1.30M | 1.23M | 1.38M |
| EBITDA | -102.04M | -57.11M | -52.27M | -31.78M | -28.36M | -32.04M | -22.00M | -11.14M | -13.91M | -12.43M | -11.42M |
| EBITDA Ratio | -583.86% | -468.92% | -1,111.99% | -7,988.71% | -392.90% | -969.50% | -287.82% | -104.86% | -268.39% | -349.37% | -337.41% |
| Operating Income | -102.71M | -57.11M | -52.11M | -29.72M | -30.31M | -33.25M | -20.92M | -13.02M | -15.51M | -13.47M | -12.47M |
| Operating Income Ratio | -587.68% | -468.92% | -1,242.58% | -7,988.71% | -433.15% | -1,040.13% | -320.76% | -137.83% | -318.17% | -410.22% | -406.81% |
| Total Other Income/Expenses | -7.11M | 2.82M | 2.84M | -3.90M | 95.00K | -111.00K | 278.00K | 460.23K | 486.14K | 745.10K | 748.35K |
| Income Before Tax | -109.82M | -54.29M | -49.27M | -33.62M | -30.22M | -33.36M | -20.64M | -12.56M | -15.02M | -12.72M | -11.72M |
| Income Before Tax Ratio | -628.36% | -445.80% | -1,174.82% | -9,037.63% | -431.79% | -1,043.57% | -316.49% | -132.96% | -308.20% | -387.52% | -382.39% |
| Income Tax Expense | 607.00K | -20.00K | 364.00K | -2.00M | 4.00K | 253.00K | -3.41M | -5.51M | -6.20M | -5.23M | -4.58M |
| Net Income | -110.43M | -54.27M | -49.64M | -31.62M | -30.22M | -33.62M | -17.23M | -7.05M | -8.82M | -7.49M | -7.13M |
| Net Income Ratio | -631.84% | -445.64% | -1,183.50% | -8,500.81% | -431.85% | -1,051.49% | -264.22% | -74.59% | -181.00% | -228.26% | -232.82% |
| EPS | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| EPS Diluted | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| Weighted Avg Shares Out | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.68M | 10.03M | 10.03M | 10.03M |
| Weighted Avg Shares Out (Dil) | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.74M | 10.03M | 10.03M | 10.03M |
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),...
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
Daix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),...
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
Inventiva announces the nomination of Andre Turenne as Director
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Inventiva reports its 2023 full-year results
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31,...
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH),...
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH),...
Source: https://incomestatements.info
Category: Stock Reports